SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Suven gets first milestone payment from Eli Lilly

Suven Life Sciences Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 530239 | NSE: SUVEN

08 Sep 2009 Evaluate

Suven Life Sciences, the Hyderabad-based biopharmaceuticals manufacturer, has received the first milestone payment for its research in developing a new drug for Eli Lilly. Suven had entered into drug discovery collaboration with the US Company in 2008 for developing a drug to treat central nervous system disorders. As part of this, Suven has announced the lead discovery leading to a milestone payment. The company would get its second milestone payment in the next nine months, which would be significant and may be achieved before the end of this financial year.

The drug being developed is a combination medicine to treat two different disorders in the same segment and is expected to be ready for the market in 2015-16. Eli Lilly is funding the entire drug development programme while Suven has the mandate to develop it as per the mutually agreed timelines. Once it is launched, Suven will keep getting the royalty till the drug is covered by the patent.

The model adopted for Eli Lilly is unique, since Suven would not invest anything as long as it sticks to the timelines. If timelines are not met than the company will have to invest for the period beyond the specified timeline. On its own, Suven has been working on developing a molecule for treating Alzheimer's, which has passed the Phase I trials.

In addition, about four pharma majors are also conducting due diligence on the Phase I data. They would also come back with their decision on buying it out in the next 3-4 months. The molecule would now move to Phase II. The proof of concept of the drug would be established after completing Phase 2a trials on humans by March 2010.

The company may not have received much in terms of dollars from the first milestone payment, but the milestone itself is a proof that it has made a good drug discovery and the company functions well in collaborative research. The company is also planning to raise about $20 million for taking the research on this molecule further. It has plans for road shows in the last quarter of this year or the first quarter of the next calendar year.crack crack

Suven Life Sciences Share Price

192.40 -2.25 (-1.16%)

13-Apr-2026 10:05 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1643.50
Dr. Reddys Lab	1214.45
Cipla	1211.30
Zydus Lifesciences	907.90
Lupin	2320.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Suven gets first milestone payment from Eli Lilly

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.